Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.

Investigational new drugs - 1 Dec 2015

Combe Pierre, Chauvenet Laure, Lefrère-Belda Marie-Aude, Blons Hélène, Rousseau Caroline, Oudard Stéphane, Pujade-Lauraine Eric

Abstract excerpt

Low-grade serous ovarian adenocarcinomas (LGSOC) make up approximately 10 % of serous ovarian carcinomas. While rarely aggressive, this slow-growing tumor is well known to respond poorly to chemotherapy. Specific treatments for this ovarian subtype are lacking, with the same global approaches used for high grade cases being applied for LGSOC patients. LGSOCs have been reported to have a specific genetic profile,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystadenocarcinoma, Serous
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Time Factors

Share to Treatment Outcome

Share to Vemurafenib

Source

Identifiers

PMID: 26490654
DOI: 10.1007/s10637-015-0297-4

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.PMID 26490654Read ↗

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.Semantic proximity Read ↗

Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.Semantic proximity Read ↗

The highs and lows of serous ovarian cancer.Semantic proximity Read ↗

Integrated genomic and histopathological analysis of low grade serous ovarian carcinoma identifies clinically distinct disease subtypesSemantic proximity Read ↗

The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity Read ↗

The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.Semantic proximity Read ↗

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesSemantic proximity Read ↗

Low-grade serous ovarian cancer: A review.Semantic proximity Read ↗

Low-grade serous ovarian carcinoma: an evolution toward targeted therapy.Semantic proximity Read ↗

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutationSemantic proximity Read ↗

Molecular characteristics and clinical behaviour of epithelial ovarian cancers.Semantic proximity Read ↗

Spectrum of BRAF Mutations and Gene Rearrangements in Ovarian Serous Carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.